Benefits
Whole-body energy expenditure and metabolic rate
In short crossover studies in healthy adults, a 40 mg dose of the seed extract raised whole-body energy expenditure measured by indirect calorimetry, and daily use over several weeks did the same. The rise was seen mainly in people who already had active brown fat. These were small studies of a metabolic reading, not of long-term outcomes.
Brown fat activation and a thermogenic response
The pungent compounds in grains of paradise act on the TRPV1 channel, the same receptor that senses chili heat. In imaging studies the extract increased energy use or cold-induced thermogenesis in volunteers with detectable brown adipose tissue, while people without active brown fat showed little change, so the effect appears to depend on having active brown fat.
Visceral fat and body fat percentage
In a 4-week crossover study in young women, 30 mg a day lowered visceral-fat area at the waist on CT, with no change in under-skin or total fat. In a 5-week study in men selected for low brown-fat activity, 40 mg a day slightly lowered body-fat percentage. Body weight itself did not change in these small studies, and the fat findings are surrogates, not weight loss.
Body weight and waist in a branded-extract trial
In a 12-week randomized trial in 70 overweight adults, a branded seed extract standardized to 6-paradol, taken at 500 mg a day, was reported to raise energy expenditure and lower visceral fat, body weight and BMI compared with placebo. The trial was funded and run by the extract's maker, and no independent group has repeated it, so treat it as single-trial evidence.
Caffeine-free metabolic support without stimulants
Grains of paradise contains no caffeine and acts through brown fat and nerve signaling rather than as a stimulant, so it has been studied as a non-stimulant option. Because the pathway raises heat production, a mild warming feeling can occur, and the measured effect still seems to depend on having active brown fat.
Mechanism of action
TRPV1 activation by pungent vanilloids
6-Paradol, 6-gingerol and 6-shogaol act on the TRPV1 channel, the vanilloid receptor also activated by capsaicin from chili peppers. In cell and animal work this is the starting point for a thermogenic response, and in people the extract's effect on energy expenditure tracks with the presence of active brown fat.
Brown adipose tissue and heat production
Brown adipose tissue burns energy to make heat using uncoupling protein 1 (UCP1), instead of storing it. Human imaging studies link the extract's rise in energy expenditure and cold-induced thermogenesis to the amount of active brown fat a person has, which is usually greater in younger, leaner people.
Exact nerve pathway is not settled
Reviews describe a TRP channel, sympathetic nerve and brown fat axis for food vanilloids, but the detail is unsettled for grains of paradise. In one rat study, grains of paradise extract and 6-gingerol lowered sympathetic nerve activity to brown fat, the opposite of capsaicin, and the authors suggested a mechanism different from capsaicin. This is animal work.
Clinical trials
Single-blind, randomized, placebo-controlled crossover study of a single 40 mg oral dose of grains of paradise extract, with brown adipose tissue status assessed by FDG-PET after 2 hours of cold exposure at 19 C and energy expenditure by indirect calorimetry (Sugita et al. 2013, Br J Nutr).
19 healthy men aged 20 to 32; 12 had detectable brown fat and 7 did not.
After the extract, whole-body energy expenditure rose within 2 hours significantly more in the men with active brown fat than in those without (P<0.01), while placebo produced no change. This is an acute metabolic reading in a small group, with no body-weight outcome, and it suggests the effect depends on having active brown fat.
Single-blind, randomized, placebo-controlled crossover study of 30 mg a day of grains of paradise extract for 4 weeks, with whole-body energy expenditure and body fat measured before and after each period; visceral fat by CT at the umbilicus (Sugita et al. 2014, J Nutr Sci Vitaminol (Tokyo)).
19 non-obese women aged 20 to 22.
Visceral-fat area fell with the extract and rose slightly on placebo, a significant difference (p<0.05) that was larger in women with more baseline visceral fat (r=-0.64, p<0.01). Subcutaneous and total fat did not change. Whole-body energy expenditure rose with the extract but not placebo. A small study of fat-distribution and metabolic surrogates, not weight loss.
Single-blind, randomized, placebo-controlled crossover study of 40 mg a day of grains of paradise extract for 5 weeks in men screened by FDG-PET/CT for low brown-fat activity, with cold-induced thermogenesis and body composition measured before and after (Yoneshiro et al. 2021, J Nutr Sci Vitaminol (Tokyo)).
9 healthy young men with reduced brown-fat activity.
Cold-induced thermogenesis after treatment was significantly higher with the extract than with placebo, while resting energy expenditure did not change. Body weight and fat-free mass did not change, and body-fat percentage fell slightly but significantly with the extract only. A very small study of a brown-fat surrogate.
Randomized, double-blind, placebo-controlled trial of a branded grains of paradise extract standardized to 6-paradol (AfperFIT), 250 mg twice daily for 12 weeks, with energy expenditure by indirect calorimetry, body composition by DEXA and fat distribution by CT; conducted and funded by the maker, Vidya Herbs (Sudeep et al. 2022, Drug Des Devel Ther).
70 overweight men and women, BMI 25 to 30, aged 20 to 50.
The extract group had higher energy expenditure (p<0.01) and, compared with placebo, reduced visceral-fat area, visceral-to-subcutaneous ratio, body weight and BMI; safety labs stayed in the normal range and no adverse effects were reported. Two of the four authors work for the maker, and no independent group has repeated the trial.
Randomized, double-blind, placebo-controlled crossover pilot of a different branded grains of paradise extract (Vanizem, standardized to 10 percent total vanilloids), at 50, 100 and 150 mg, each dose taken for two days with questionnaires 48 hours after the first capsule; this tested a different outcome from the weight studies and was funded by the maker, Nektium (Perez-Machin et al. 2025, Pharmaceuticals (Basel)).
45 adults screened, 37 randomized and 30 completed, aged 40 to 50, all with moderate anxiety (18 to 24 on a modified Hamilton Anxiety Rating Scale) at entry.
Over each 2-day intake, self-rated anxiety and stress-related tension scores fell and mood and sleep-quality questionnaires improved at 50 to 150 mg, with no side effects reported. The mood and endocannabinoid receptor work in the same paper was done in the test tube. This is a 30-person pilot of questionnaires with nothing measured past 48 hours, and three authors work for the maker.